MCK

McKesson Corp

Add to Watchlist

Advanced Chart

711.210

+1.41(0.199%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

714.740

Open

707.200

VWAP

710.37

Vol

395.79K

Mkt Cap

88.83B

Low

702.000

Amount

281.15M

EV/EBITDA(TTM)

15.68

Total Shares

129.71M

89.00B

EV/OCF(TTM)

14.63

P/S(TTM)

0.25

McKesson Corporation is a diversified healthcare services company, which focuses on advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. It also offers oncology and specialty solutions.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q3

FY2026Q2

FY2026Q1

105.35B

+10.56%

9.746

+21.37%

103.73B

+10.76%

8.802

+24.5%

96.17B

+21.3%

8.180

+3.8%

Estimates Revision

The market is revising Upward the revenue expectations for McKesson Corporation (MCK) for FY2026, with the revenue forecasts being adjusted by 1.47% over the past three months. During the same period, the stock price has changed by 4.21%.

Revenue Estimates for FY2026

Revise Upward

+1.47%

In Past 3 Month

EPS Estimates for FY2026

Revise Upward

+1.44%

In Past 3 Month

Stock Price

Go Up

+4.21%

In Past 3 Month

12 Analyst Rating

10.73% Upside

Wall Street analysts forecast MCK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MCK is 787.55 USD with a low forecast of 735.00 USD and a high forecast of 820.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

2 Hold

0 Sell

Strong Buy

10.73% Upside

Current: 711.210

Low

735.00

Averages

787.55

High

820.00

10.73% Upside

Current: 711.210

Low

735.00

Averages

787.55

High

820.00

Morgan Stanley

NULL -> Overweight

maintain

$770 -> $810

2025-07-16

Reason

Morgan Stanley

Price Target

$770 -> $810

2025-07-16

maintain

NULL -> Overweight

Reason

Morgan Stanley raised the firm's price target on McKesson to $810 from $770 and keeps an Overweight rating on the shares.

Morgan Stanley

Erin Wright

Overweight

maintain

$745 -> $770

2025-06-11

Reason

Morgan Stanley

Erin Wright

Price Target

$745 -> $770

2025-06-11

maintain

Overweight

Reason

Wells Fargo

Stephen Baxter

Equal Weight

maintain

$691 -> $766

2025-06-03

Reason

Wells Fargo

Stephen Baxter

Price Target

$691 -> $766

2025-06-03

maintain

Equal Weight

Reason

Wells Fargo analyst Stephen Baxter raised the firm's price target on McKesson to $766 from $691 and keeps an Equal Weight rating on the shares. The firm is updating its model following Q4 earnings and fiscal 2026 guide. Wells remains on the sidelines given premium vs. peers required despite what it sees as more exposure to overhangs.

TD Cowen

Buy

upgrade

$695 -> $820

2025-05-12

Reason

TD Cowen

Price Target

$695 -> $820

2025-05-12

upgrade

Buy

Reason

TD Cowen raised the firm's price target on McKesson to $820 from $695 and keeps a Buy rating on the shares. The firm updated its estimates following Q4 results which assume no sale of the Med-Surg segment and includes contributions from FCS and PRISM Vision.

BofA

Buy

maintain

$755 -> $800

2025-05-09

Reason

BofA

Price Target

$755 -> $800

2025-05-09

maintain

Buy

Reason

B of A Securities

Michael Cherny

Strong Buy

Maintains

$665 → $755

2025-04-11

Reason

B of A Securities

Michael Cherny

Price Target

$665 → $755

2025-04-11

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for McKesson Corp (MCK.N) is 18.98, compared to its 5-year average forward P/E of 13.80. For a more detailed relative valuation and DCF analysis to assess McKesson Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Overvalued

5Y Average PE

13.80

Current PE

18.98

Overvalued PE

17.11

Undervalued PE

10.48

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Overvalued

5Y Average EV/EBITDA

10.51

Current EV/EBITDA

13.74

Overvalued EV/EBITDA

12.82

Undervalued EV/EBITDA

8.20

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Overvalued

5Y Average PS

0.17

Current PS

0.22

Overvalued PS

0.20

Undervalued PS

0.13